切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2024, Vol. 13 ›› Issue (04) : 236 -239. doi: 10.3877/cma.j.issn.2095-3216.2024.04.011

病例报告

腹膜透析相关嗜酸粒细胞性腹膜炎:1例报告及文献回顾
刘静1, 王兴华1, 高玉伟1, 胡秀红1, 崔红蕊1, 徐保振1, 杨洪娟1, 王涛1,()   
  1. 1. 050030 石家庄,河北医科大学第一医院肾脏内科
  • 收稿日期:2023-07-07 出版日期:2024-08-28
  • 通信作者: 王涛
  • 基金资助:
    河北省中医药管理局科研项目(2024027)

Peritoneal dialysis-associated eosinophilic peritonitis: a case report and literature review

Jing Liu, Xinghua Wang, Yuwei Gao   

  • Received:2023-07-07 Published:2024-08-28
引用本文:

刘静, 王兴华, 高玉伟, 胡秀红, 崔红蕊, 徐保振, 杨洪娟, 王涛. 腹膜透析相关嗜酸粒细胞性腹膜炎:1例报告及文献回顾[J]. 中华肾病研究电子杂志, 2024, 13(04): 236-239.

Jing Liu, Xinghua Wang, Yuwei Gao. Peritoneal dialysis-associated eosinophilic peritonitis: a case report and literature review[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(04): 236-239.

腹膜透析相关性腹膜炎(peritoneal dialysis-associated peritonitis,PDAP)是腹膜透析(peritoneal dialysis,PD)较严重、预后较差的并发症。嗜酸性粒细胞性腹膜炎是一种特殊类型的非感染性的PDAP,多在腹膜透析液细菌培养阴性的腹膜炎病例中发生,其病因及病理机制至今仍不完全清楚。嗜酸性粒细胞性腹膜炎主要被认为是腹膜对异物的过敏反应,但也可以在腹膜透析液细菌培养阳性的腹膜炎发作后发生。近年来随着腹膜透析技术的推广及发展,嗜酸性粒细胞性腹膜炎的临床报道有所增加,但国内报道相对较少。现将我院诊治的1例腹膜透析相关嗜酸性粒细胞性腹膜炎患者进行总结报道,并对期的临床特征和治疗方式进行详细的文献综述,以期减少临床误诊及漏诊。

表1 患者住院期间主要实验室检查指标监测
图1 住院期间患者腹膜透析液白细胞计数及嗜酸粒细胞比率变化
图2 随访期间患者腹膜透析液白细胞计数及嗜酸粒细胞比率变化
表2 嗜酸粒细胞性腹膜炎常见的病因
[1]
蔡士铭,燕宇,赵慧萍,等. 腹膜透析相关嗜酸粒细胞性腹膜炎1例报道并文献复习[J] .北京大学学报(医学版), 2018, 50(4): 747-751.
[2]
Albilali AS, Rahim KA, Edrees BM, et al. Resolution of eosinophilic peritonitis with oral prednisolone in a child receiving peritoneal dialysis [J]. Perit Dial Int, 2011, 31(3): 359-360.
[3]
Lee S, Schoen I. Eosinophilia of peritoneal fluid and peripheral blood associated with chronic peritoneal dialysis [J]. Am J Clin Pathol, 1967, 47(5): 638-640.
[4]
Fontán MP, Rodríguez-Carmona A, Galed I, et al. Incidence and significance of peritoneal eosinophilia during peritoneal dialysis-related peritonitis [J]. Perit Dial Int, 2003, 23(5): 460-464.
[5]
Jo YI, Song JO, Park JH, et al. Idiopathic eosinophilic peritonitis in continuous ambulatory peritoneal dialysis: experience with percutaneous catheter placement [J]. Nephrology (Carlton), 2007, 12(5): 437-440.
[6]
阿比囡扎,董捷. 腹膜透析患者腹水嗜酸性粒细胞增多的研究现状[J] .中华肾脏病杂志2022, 38(3): 241-246.
[7]
Suzuki R, Sato M, Murakoshi M, et al. Eosinophilic peritonitis in children on chronic peritoneal dialysis [J]. Pediatr Nephrol, 2021, 36(6): 1571-1577.
[8]
Deweese R, Slavens J, Barua A, et al. Vancomycin-induced eosinophilic peritonitis [J]. Am J Health-Syst Pharm, 2016, 73(9): 243-246.
[9]
Rosner MH, Chhatkuli B. Vancomycin-related eosinophilic peritonitis [J]. Perit Dial Int, 2010, 30(6): 650-652.
[10]
Wang Z, Li Z, Luo S, et al. Cefoperazone and sulbactam-related eosinophilic peritonitis: a case report and literature review [J]. J Int Med Res, 2021, 49(6): 1-7.
[11]
Minato S, Miyazawa H, Kitano T, et al. Eosinophilic peritonitis induced by sucroferric oxyhydroxide [J]. Perit Dial Int, 2020, 40(4): 419-421.
[12]
Ohnmacht C, Pullner A, van Rooijen N, et al. Analysis of eosinophil turnover in vivo reveals their active recruitment to and prolonged survival in the peritoneal cavity [J]. J Immunol, 2007, 179(7): 4766-4774.
[13]
Gauckler P, Shin JI, Mayer G, et al. Eosinophilia and kidney disease: more than just an incidental finding? [J]. J Clin Med, 2018, 7(12): 529.
[14]
Roberts RL, Ank BJ, Stiehm ER. Human eosinophils are more toxic than neutrophils in antibody-independent killing [J]. J Allergy Clin Immunol, 1991, 87(6): 1105-1115.
[15]
Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease [J]. Clin Exp Allergy, 2008, 38(5): 709-750.
[16]
Zhou Q, Bajo MA, Del Peso G, et al. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients [J]. Kidney Int, 2016, 90(3): 515-524.
[17]
Chan MK, Chow L, Lam SS, et al. Peritoneal eosinophilia in patients on continuous ambulatory peritoneal dialysis: a prospective study [J]. Am J Kidney Dis, 1988, 11(2): 180-183.
[18]
Yuzawa Y, Ito Y, Mizuno M, et al. Pathological changes in chronic eosinophilic peritonitis in peritoneal dialysis patient [J]. NDT Plus, 2010, 3(4): 372-375.
[19]
Scherer K, Brockow K, Aberer W, et al. Desensitization in delayed drug hypersensitivity reactions--an EAACI position paper of the Drug Allergy Interest Group [J]. Allergy, 2013, 68(7): 844-852.
[20]
Shigemoto E, Mizuno M, Suzuki Y, et al. Increase of eosinophils in dialysate during induction of peritoneal dialysis [J]. Perit Dial Int, 2019, 39(1): 90-92.
[21]
Cetin N, Sav NM, Ciftci E, et al. Foreign body reaction to dialysis chatheter and peritoneal fluid eosinophilia in a child on continuous ambulatory peritoneal dialysis [J]. Iran J Kidney Dis, 2017, 11(4): 319-321.
[22]
Xu Y, Gao C, Xu J, et al. Successful treatment of idiopathic eosinophilic peritonitis by oral corticosteroid therapy in a continuous ambulatory peritoneal dialysis patient [J]. Case Rep Nephrol Dial, 2015, 5(2): 130-134.
[23]
Arata R, Banshodani M, Yamashita M, et al. Perforative peritonitis confused with peritoneal dialysis-related peritonitis: Report of three cases [J]. Int J Surg Case Rep, 2020, 70: 20-23.
[24]
Semerci N, Sonmez F, Özkısacık S, et al. Cloudy peritoneal fluid-eosinophilic peritonitis [J]. Turk Nephrol Dial Transpl J, 2007, 16: 154-156.
[25]
Quinlan C, Cantwell M, Rees L. Eosinophilic peritonitis in children on chronic peritoneal dialysis [J]. Pediatr Nephrol, 2010, 25(3): 517-522.
[26]
Forbes TA, Lunn AJ. Montelukast: a novel therapeutic option in eosinophilic peritonitis [J]. Pediatr Nephrol, 2014, 29(7): 1279-1282.
[27]
Shin Y-W, Bae E-A, Lee B, et al. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components [J]. Planta Med, 2007, 73(3): 257-261.
No related articles found!
阅读次数
全文


摘要